Psoriasis
Conditions
Keywords
psoriasis, topical, psoriasis plaques test
Brief summary
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
Interventions
DRUGLAS 41004
LAS 41004 dosage 1, once daily
DRUGLAS 41004 dosage 6
LAS 41004, dosage 6, once daily
DRUGPlacebo
Placebo, once daily
DRUGReference
Reference, once daily
Sponsors
Almirall, S.A.
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients between 18 and 75 years of age with a diagnosis of stable plaque-type psoriasis (psoriasis vulgaris) for at least 6 month * Psoriasis plaques that are suitable to be defined as target area lesions by the following criteria: 1. Psoriasis plaques must be located at trunk and/or extremities. Plaques that are located on the head (incl. scalp), palms, sole of the feet, intertriginous or genitoanal areas are not suitable as target areas 2. Comparable psoriasis plaques with at least 2 in each score (Range 0-4) for the three distinct symptoms scaling; erythema; and induration 3. No more than 3 points difference in total score (= sum of scores for scaling, erythema and induration; Range 0-12) of the chosen comparable psoriasis plaques 4. Enough psoriatic surface area to define 8 clearly distinguishable (minimum distance between test areas: 1cm) test areas of at least 1 cm² plaque size * Patient is willing and able to comply with the requirements of the clinical study protocol. In particular, patient must adhere to concomitant therapy prohibitions of the test areas and must agree to avoid intense UV exposure of the test areas during the study * Written informed consent to participate in the study, prior to any study related procedures, indicating an understanding of the purpose of the study * A patient of childbearing potential agrees to use one of the following contraceptive methods for the duration of the study: 1. Strict abstinence (exception: male partner with a vasectomy for at least 3 months prior to study entry is allowed) 2. Combined oral, implanted or injectable contraceptives on a stable dose for at least 3 months prior to study entrance 3. Intrauterine device (IUD) inserted for at least 1 month prior to study entrance
Exclusion criteria
* Too few body surface area covered with psoriasis plaques that meet the specified inclusion criteria to be defined as 8 clearly distinguishable test areas * Any condition that may interfere with the study assessments or sonographic measurements of the skin and/or may have an influence on skin immune response (incl. open wounds) * Known adverse reactions of any severity or hypersensitivity to any ingredient of the test products * No willingness to avoid induction of heavy sweating, e.g. due to sauna visits, excessive sports activities during the study course * No willingness to avoid swimming, bathing or wetting of the designated test areas between visits * Pregnant or breast-feeding women * A medical condition that may put the patient at a general risk and therefore would prevent participation in the clinical trial (including but not limited to: serious infectious diseases, major surgery within the last 4 weeks, coronary artery disease, renal impairment, hepatic impairment, uncontrolled metabolic diseases, disorders of the calcium metabolism, autoimmune diseases) * History or presence of malignant disease (other than surgically removed basal cell carcinoma) and/or auto immune diseases * Current diagnosis of guttate, erythrodermic or pustular psoriasis * Patients who did not respect the following wash-out periods prior or during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in skin thickness | 15 days | measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in erythema score | 15 days | scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| change in induration score | 15 days | scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| change in clinical score | 15 days | scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
| Number of skin reactions per patient as a measure of safety and tolerability | 15 days | scoring will be performed by investigator |
| Number of Adverse Events per patients as a measure of safety and tolerability | 15 days | reporting will be performed by investigator |
| change in scaling score | 15 days | scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15) |
Countries
Germany
Outcome results
None listed